Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ISRCTN10344823) titled 'Impact of Symprove in irritable bowel syndrome' on May 20.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Supportive care
Primary Sponsor: Symprove Ltd
Condition:
Irritable bowel syndrome (IBS)
Digestive System
Intervention:
All participants will receive a 12-week course of Symprove (70 ml per day), a water-based solution that contains billions of live and active bacteria. Participants will also complete study surveys at weeks 4, 8 and 12. The study does not involve any study visits.
Recruitment St...